Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

CME

Cervical Cancer

19 Nov 2019

neoadjuvant chemotherapy with cisplatin and gemcitabine prior to chemoradiation may reduce survival compared to chemoradiation alone in women with locally advanced stage IIB-IVA cervical cancer (J Clin Oncol 2019 Nov 20)

19 Nov 2019

neoadjuvant chemotherapy with cisplatin and gemcitabine prior to chemoradiation may reduce survival compared to chemoradiation alone in women with locally advanced stage IIB-IVA cervical cancer (J Clin Oncol 2019 Nov 20)

24 Jan 2019

previous HPV-related vulvovaginal cancer, cervical intraepithelial neoplasia, and oropharyngeal cancer each associated with increased risk of primary HPV-related cervical cancer (Br J Cancer 2018 Nov 28)

24 Jan 2019

previous HPV-related vulvovaginal cancer, cervical intraepithelial neoplasia, and oropharyngeal cancer each associated with increased risk of primary HPV-related cervical cancer (Br J Cancer 2018 Nov 28)

15 Nov 2018

laparoscopic or robot-assisted radical hysterectomy associated with reduced 2.5-year overall survival and disease-free survival compared to open abdominal radical hysterectomy in women with early-stage cervical cancer (N Engl J Med 2018 Nov 15)

15 Nov 2018

laparoscopic or robot-assisted radical hysterectomy associated with reduced 2.5-year overall survival and disease-free survival compared to open abdominal radical hysterectomy in women with early-stage cervical cancer (N Engl J Med 2018 Nov 15)

29 Oct 2018

adjuvant intensity-modulated pelvic radiation therapy may reduce gastrointestinal and urinary toxicity at 5 weeks compared to standard 4-field pelvic radiation therapy in women with invasive cervical or endometrial cancer (J Clin Oncol 2018 Aug 20)

29 Oct 2018

adjuvant intensity-modulated pelvic radiation therapy may reduce gastrointestinal and urinary toxicity at 5 weeks compared to standard 4-field pelvic radiation therapy in women with invasive cervical or endometrial cancer (J Clin Oncol 2018 Aug 20)

11 May 2018

addition of bevacizumab to chemotherapy associated with increased overall survival for up to 26 months in women with metastatic, persistent, or recurrent cervical cancer (Lancet 2017 Oct 7)

11 May 2018

addition of bevacizumab to chemotherapy associated with increased overall survival for up to 26 months in women with metastatic, persistent, or recurrent cervical cancer (Lancet 2017 Oct 7)

top

Subscribe for unlimited access to DynaMed content.
Already subscribed? Sign in